Ontuxizumab
- Generic Name
- Ontuxizumab
- Drug Type
- Biotech
- CAS Number
- 946415-62-9
- Unique Ingredient Identifier
- 0M2XT000YC
- Background
Ontuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 (TEM-1). It is under investigation in clinical trial NCT01574716 (Sarcoma Study of Morab-004 Utilization: Research and Clinical Evaluation).
A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2016-11-10
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT01773434
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
- Conditions
- Metastatic Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2012-04-10
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 209
- Registration Number
- NCT01574716
- Locations
- ๐บ๐ธ
Sarcoma Oncology Center, Santa Monica, California, United States
๐บ๐ธSidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
- Conditions
- Colorectal CancerMetastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2012-01-11
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 154
- Registration Number
- NCT01507545
- Locations
- ๐บ๐ธ
Providence St. Joseph Medical Center-Disney Family Cancer Center, Burbank, California, United States
๐บ๐ธSt. Jude Heritage Healthcare, Fullerton, California, United States
๐บ๐ธComprehensive Blood and Cancer Center, Bakersfield, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.